Last reviewed · How we verify
Intensified TBM treatment
Intensified TBM treatment uses higher doses and/or more frequent administration of anti-tuberculous drugs to improve penetration into the central nervous system and enhance bacterial killing in tuberculous meningitis.
Intensified TBM treatment uses higher doses and/or more frequent administration of anti-tuberculous drugs to improve penetration into the central nervous system and enhance bacterial killing in tuberculous meningitis. Used for Tuberculous meningitis (TBM).
At a glance
| Generic name | Intensified TBM treatment |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Tuberculous meningitis (TBM) is a severe form of tuberculosis affecting the brain and spinal cord membranes, with poor drug penetration across the blood-brain barrier being a major treatment challenge. Intensified regimens aim to achieve higher cerebrospinal fluid (CSF) concentrations of first-line anti-TB agents (isoniazid, rifampicin, pyrazinamide, ethambutol) through increased dosing or dosing frequency, thereby improving bacterial sterilization and clinical outcomes. This approach is being evaluated in phase 3 trials to establish optimal dosing strategies for this life-threatening infection.
Approved indications
- Tuberculous meningitis (TBM)
Common side effects
- Hepatotoxicity
- Peripheral neuropathy
- Gastrointestinal disturbance
- Ototoxicity
Key clinical trials
- Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis (PHASE3)
- Intensified Short Course Regimen for TBM in Adults (PHASE3)
- Pharmacokinetic Study of Linezolid for TB Meningitis (PHASE2)
- Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intensified TBM treatment CI brief — competitive landscape report
- Intensified TBM treatment updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI